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Abstract
Elevated plasma lipopolysaccharide (LPS), an indicator of microbial translocation from the gut, is a likely cause of systemic
immune activation in chronic HIV infection. LPS induces monocyte activation and trafficking into brain, which are key
mechanisms in the pathogenesis of HIV-associated dementia (HAD). To determine whether high LPS levels are associated
with increased monocyte activation and HAD, we obtained peripheral blood samples from AIDS patients and examined
plasma LPS by Limulus amebocyte lysate (LAL) assay, peripheral blood monocytes by FACS, and soluble markers of
monocyte activation by ELISA. Purified monocytes were isolated by FACS sorting, and HIV DNA and RNA levels were
quantified by real time PCR. Circulating monocytes expressed high levels of the activation markers CD69 and HLA-DR, and
harbored low levels of HIV compared to CD4
+ T-cells. High plasma LPS levels were associated with increased plasma sCD14
and LPS-binding protein (LBP) levels, and low endotoxin core antibody levels. LPS levels were higher in HAD patients
compared to control groups, and were associated with HAD independently of plasma viral load and CD4 counts. LPS levels
were higher in AIDS patients using intravenous heroin and/or ethanol, or with Hepatitis C virus (HCV) co-infection,
compared to control groups. These results suggest a role for elevated LPS levels in driving monocyte activation in AIDS,
thereby contributing to the pathogenesis of HAD, and provide evidence that cofactors linked to substance abuse and HCV
co-infection influence these processes.
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Introduction
Immune activation is a strong predictor of HIV disease
progression [1,2]. Elevated plasma endotoxin (bacterial lipopoly-
saccharide, LPS, a component of Gram-negative bacteria), a
consequence of translocation of bacterial products from a leaky
gut, is a likely cause of immune activation in HIV infection [3].
LPS triggers monocyte (Mo) activation via CD14 and TLR4-
mediated signaling, resulting in release of soluble CD14 and pro-
inflammatory cytokines. Sustained Mo stimulation leads to LPS
tolerance [4]. Brenchley et al. found correlations between plasma
LPS levels, Mo tolerance to LPS ex vivo, and T-cell activation
markers, and proposed that T-cell activation is an indirect
consequence of LPS-mediated Mo stimulation [3].
Alterations in circulating Mo linked to HIV disease progression
include increased expression of pro-inflammatory cytokines and
Mo activation markers [5,6,7]. CD16/FccRIII expression on Mo
distinguishes a minor CD16
+ subset [8,9] that expresses higher
TNF and IL-1 [5], and higher HLA-DR, CD40, and CD86 levels
compared to CD16
2 Mo. CD16
+ Mo represent 5–10% of
circulating Mo in healthy individuals [8], but are dramatically
expanded in HIV-infected patients [5,10], particularly during
progression to AIDS [6,7]. Although Mo do not support
productive HIV infection in vitro [11] and represent a minor
viral reservoir in HIV-infected patients [12,13,14], CD16
+ Mo
may be preferentially susceptible to infection [14,15,16]. Further-
more, CD16
+ Mo-derived macrophages form conjugates with T-
cells that promote T-cell activation and HIV replication [17,18].
Activated Mo play a key role in the pathogenesis of HIV-
associated dementia (HAD) and minor cognitive motor disorder
(MCMD) [7,19,20,21,22] by carrying virus into the CNS,
supporting productive infection upon differentiation into macro-
phages, and producing neurotoxic factors [7,21]. An increased
frequency of CD16
+/CD69
+ activated Mo [5] was associated with
HAD in the pre-HAART era [6,7]. HAART decreases the
frequency of CD16
+ Mo [10], reduces HIV levels in brain, and
improves neurocognitive function [19], but neurocognitive
impairment (NCI) still occurs in ,10–20% of AIDS patients
PLoS ONE | www.plosone.org 1 June 2008 | Volume 3 | Issue 6 | e2516[19,20,21]. Host factors that drive Mo activation in patients who
develop HAD have not been defined.
Here we investigated the relationship between plasma LPS,
alterations in circulating Mo, and HAD in AIDS patients. High
plasma LPS and LPS-binding protein (LBP) levels, together with
low endotoxin core antibody (EndoCAb) levels, were associated
with increased soluble markers of Mo activation and HAD. Plasma
LPS levels were higher in AIDS subjects with IV heroin or ethanol
abuse, or co-infection with Hepatitis C virus (HCV) compared to
control groups. These findings suggest a role for elevated LPS
levels in triggering Mo activation during HIV infection, thereby
contributing to HAD pathogenesis, and identify cofactors that may
influence these processes.
Materials and Methods
Subjects
AIDS patients with CD4 counts ,300 cells/ml were recruited at
the Lemuel Shattuck Hospital (n=49) or at 4 sites in the National
NeuroAIDS Tissue Consortium (NNTC) (Manhattan HIV Brain
Bank, National Neurological AIDS Bank, California NeuroAIDS
Tissue Network, Texas NeuroAIDS Research Center) (n=70)
with written informed consent and IRB approval. HIV-/HCV-
uninfected blood was from Research Blood Components
(Brighton, MA). Shattuck Hospital subjects were recruited based
on presence or absence of an HAD diagnosis. NNTC subjects
were selected by database searches based on patterns of substance
abuse (determined by PRISM (psychiatric research interview for
substance and mental disorders) diagnoses and urine tox screens)
irrespective of HAD or other forms of NCI. HAD or MCMD
diagnoses were determined using American Academy of Neurol-
ogy diagnostic criteria [19,23] and asymptomatic neurocognitive
impairment (ANI) diagnosis was determined using HIV Neurobe-
havioral Research Center (HNRC) criteria [24] based on formal
neurocognitive testing and/or neurological evaluation and lack of
other known cause for NCI. Patients with severe psychiatric
diagnoses that might confound neurological evaluation, a
confounding neurological disorder (i.e., CNS opportunistic
infection, brain neoplasm), or active bacterial or opportunistic
infection were excluded.
Antibodies
Fluorochrome-conjugated Abs used for FACS analysis were
CD14, CD16, CD19, CD33, CD16b, CD66b, CD56, and CD3
(Beckman Coulter); CD4, CCR5, CD69, and HLA-DR (BD
Pharmingen).
Cell sorting
PBMC were isolated from peripheral blood by Ficoll-Paque
centrifugation [17,25]. Mo were isolated by negative selection using
immunobeads (Miltenyi) [17,25] or by FACS sorting. CD3
+ T-cells
were isolated using CD3 immunobeads (Miltenyi), and CD4
+ T-cells
were sorted by FACS. PBMC depleted of CD3
+ T-cells were stained
with PE-CD14 and PE-Cy5 CD16 Abs and FITC-conjugated Abs
against T-cell (CD3), granulocyte (CD16b/CD66b), B cell (CD19),
NK cell (CD56), and dendritic cell (CD1c) markers. Sorted T-cells
and Mo were .98% pure as determined by FACS.
Quantification of HIV DNA and RNA
HIV DNA and RNA in CD4
+ T-cells and Mo were quantified
by real time PCR and RT-PCR (sensitive to 50 copies). Total
DNA and RNA was isolated using Qiagen DNA-EZ and RNA-EZ
isolation kits. DNA from 10
5 cells was amplified for 45 cycles using
Taqman Universal PCR Master Mix (Applied Biosystems) and
HIV Gag primers and probe [26]. Sequential dilutions of 8E5 cells
were used to quantify Gag and CCR5 copy number. For qRT-
PCR, RNA from 10
5 cells was reverse transcribed using the High
Capacity cDNA Archive kit (Applied Biosystems) and amplified
with HIV Gag primers and probes [26].
Isolation of replication-competent HIV
CD4
+ T-cells and Mo isolated from HIV-infected patients were
cultured with Mo:CD4
+ T-cell co-cultures from a HIV-uninfected
donor pre-stimulated with PHA/IL-2 as described, a method that
isolates both CCR5 and CXCR4-using HIV strains efficiently
[17,18,27]. HIV p24 was quantified in culture supernatants by
ELISA (Perkin Elmer).
Quantification of plasma LPS, lipopolysaccaride binding-
protein, IgM endotoxin core antibody, soluble CD14, IL-6,
and CCL2
Plasma LPS levels were quantified using the Diazo-coupled
Limulus amebocyte lysate (LAL) assay (Associates of Cape Cod
Inc.) according to manufacturer’s protocol. Briefly, samples diluted
1/5 were inactivated for 30 min at 65uC and incubated with LAL
for 30 min at 37uC. Addition of reagents led to formation of a
magenta derivative that absorbs light at 570 nm. Plasma soluble
CD14 (sCD14), IL-6, and CCL2 levels were quantified by ELISA
(R&D Systems). Lipopolysaccharide binding-protein (LBP) and
IgM endotoxin core antibody (EndoCAb) levels in plasma were
quantified by ELISA (Cell Sciences).
Results
Increased plasma LPS and sCD14 are associated with
HAD
To investigate the potential role of circulating LPS in triggering
Mo activation, plasma LPS levels together with soluble markers of
Mo activation (i.e., sCD14 [3], IL-6, and CCL2 [28]) were
compared between AIDS patients classified according to NCI
diagnoses into 5 groups (No NCI, HAD, MCMD, neuropsychiatric
impairment due to cause other than HIV (NPI-O), and ANI). The
cohort consisted of 119 AIDS patients enrolled at the Shattuck
Hospital (n=49) or NNTC (n=70) (Table 1), and had relatively
high plasma VL and low CD4 counts compared to other current
cohorts, together with a high frequency of intravenous drug abuse
(IVDU). 61 of 94 subjects were HAART failures (.1,000 HIV
RNA copies/ml), 11 were on HAART ,8 weeks, and 14 were not
on HAART. Plasma levels of LPS, sCD14, IL-6, and CCL2 were
higher in AIDS compared to uninfected subjects (Figure 1A).
Plasma LPS levels correlated positively with sCD14 (Figure 1B), but
not CCL2 or IL-6. sCD14 levels correlated positively with CCL2,
IL-6 (Figure 1B), and plasma VL (p=0.03; r=0.19) and negatively
with CD4 counts (p=0.0012, r=20.29). Significant differences in
plasma VL, LPS, sCD14, IL-6, and CCL2 but not CD4 counts,
were observed between the NCI groups (Kruskal-Wallis, p ,0.05).
Plasma VL was higher in HAD and NPI-O subjects compared to
those with no NCI. CD4 counts trended toward lower levels in
HAD or MCMD subjects compared to those with no NCI
(Figure 1C). Compared to subjects with no NCI, LPS levels were
higher in HAD, sCD14 and CCL2 levels were higher in HAD,
MCMD, and NPI-O, and IL-6 levels were higher in MCMD and
NPI-O subjects (Figure 1C). In patients with CD4 counts ,100,
LPS and sCD14 levels were also higher in HAD subjects (median,
106.5 pg/ml LPS and 2.65 mg/ml sCD14) compared to those with
no NCI (median, 68.1 pg/ml LPS and 2.45 mg/ml sCD14;
p=0.0079 and p=0.024, respectively).
LPS and AIDS Dementia
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frequency of HAD, but not MCMD, NPI-O, or ANI (Tables 2 and
3). Multivariate analysis in logistic regression models demonstrated
that LPS levels were a predictor of HAD independently of plasma
VL and CD4 counts, whereas sCD14 levels were a predictor of
HAD independently of plasma VL and LPS, but in relationship
with CD4 counts and plasma levels of CCL2 and IL-6 (p,0.05).
Substance abuse and HCV coinfection are associated
with high plasma LPS
An increased incidence of bacterial infections occurs in IVDU
[29,30]. Whether LPS levels are influenced by substance abuse in
AIDS patients is unknown. The study cohort included many
subjects with active IVDU or other types of substance abuse. We
therefore examined the relationship between specific patterns of
Figure 1. Increased plasma LPS, sCD14, and CCL2 are associated with HAD. (A) Levels of LPS, sCD14, CCL2, and IL-6 were quantified in
plasma of AIDS patients (n=119) and uninfected controls (n=25). (B) Spearman correlation (r and p-values) was calculated to determine the
relationship between the LPS levels and sCD14, and between sCD14 and plasma CCL2 or IL-6. (C) Levels of plasma VL, CD4 counts, LPS, sCD14, CCL2,
and IL-6 were compared in AIDS patients classified in 5 groups based on the degree of neurocognitive impairment (NCI) (None, No NCI; HAD, HIV-
associated dementia; MCMD, minor cognitive and motor disorder; NPI-O, neuropsychiatric impairment due to conditions other than HIV; and ANI,
asymptomatic NCI). Kruskal-Wallis test determined significant differences between the 5 groups in 1C. Median values in 1A and 1C are indicated as
horizontal lines and significant differences between the 4 NCI groups versus the no NCI group (None) were determined using the Mann-Whitney test.
doi:10.1371/journal.pone.0002516.g001
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classified into 4 groups based on patterns of substance abuse: no
substance abuse, IVDU (H, heroin, C, cocaine, and H+C, both
heroin and cocaine), non-intravenous cocaine (i.e., via mucosal
routes), and ethanol. Significant differences in plasma VL, LPS,
and CD4 counts, but not sCD14 levels, were observed between
groups (Figure 2A–B) (Kruskal-Wallis, p,0.05). IVDU, but not
non-intravenous cocaine abuse, was associated with higher plasma
LPS levels, while plasma VL and CD4 counts were lower and
higher, respectively, in IVDU subjects compared to those with no
substance abuse (Figure 2A). Ethanol abuse was associated with
higher plasma LPS levels but no significant differences in plasma
VL or CD4 counts compared to the control group (Figure 2A).
IVDU heroin users, but not IVDU heroin/cocaine or cocaine
users, had higher plasma LPS levels despite lower plasma VL and
higher CD4 counts compared to subjects with no substance abuse
(Figure 2B). Thus, IV heroin and ethanol abuse are associated with
increased plasma LPS levels in AIDS patients.
The liver plays a critical role in the response to infections and
LPS clearance [31,32]. HCV co-infection is frequent in IVDU,
and has been associated with an increased incidence of NCI in
AIDS patients [33,34,35]. Plasma LPS, but not sCD14 levels, were
higher in AIDS patients co-infected with HCV compared to
HCV- subjects, even though plasma VL was lower and CD4
counts were higher in HCV+ compared to HCV- subjects
(Figure 2C). Among HCV+ subjects, LPS levels were higher in
IVDU compared to subjects with remote or no substance abuse
(93.8 versus 39.5 pg/ml LPS, median, n=34 and n=6, respec-
tively, p=0.009). Thus, HCV and IVDU are independently
associated with increased LPS in AIDS patients.
Increased LBP and decreased EndoCAb levels are
associated with HAD
Increased LPS in the circulation promotes hepatic synthesis of
LBP, a plasma protein that increases the binding of LPS to CD14.
In some clinical studies, plasma LBP levels reflected long-term
exposure to circulating endotoxin more accurately than plasma
endotoxin levels [36,37]. Microbial translocation in HIV-infected
patients is associated with increased LBP levels and decreased IgM
antibodies to the LPS core oligosaccharide (EndoCAb) [3]. We
measured plasma levels of LBP and EndoCAb in AIDS patients
with and without NCI and uninfected controls, and found that
LBP levels were significantly higher in AIDS patients compared to
uninfected subjects (Figure 3A) and correlated positively with
plasma LPS (Figure 3B). Plasma LBP levels were significantly
higher in HAD subjects compared to those with no NCI
(Figure 3C). Among subjects classified according to different
patterns of substance abuse, LBP levels were higher in subjects
with active heroin IVDU or ethanol abuse compared to those with
no substance abuse (Figures 3D–E). Plasma IgM EndoCAb levels
were significantly lower in AIDS compared to uninfected subjects
(Figure 4A) and correlated negatively with plasma LPS levels
(Figures 4B). Plasma EndoCAb levels were slightly lower in AIDS
Table 1. Demographic and clinical characteristics of AIDS
patients in the study cohort.
Gender Male n=89
Female n=30
Race Hispanic n=25
Caucasian n=48
African American n=43
Other n=3
HAART $8 weeks n=94
,8 weeks n=11
None n=14
Risk Factor Sexual transmission n=66
Intravenous drug use n=53
Neurocognitive
impairment (NCI)
No NCI n=32
HAD n=28
MCMD n=25
NPI-O n=20
ANI n=9
Unable to assign n=5
Age (years) Mean6SD 4568
Median (range) 44 (25–69)
Plasma HIV RNA
(copies/ml)
Mean6SD 150,6006330,100
Median (range) 19,940 (,50–2,210,000)
CD4 T-cell count (cells/ml) Mean6SD 1106197
Median (range) 64 (1–299)
HAART, highly active antiretroviral therapy; NCI, neurocognitive impairment;
HAD, HIV-associated dementia, MCMD, minor cognitive and motor disorder;
NPI-O, neuropsychiatric impairment due to conditions other than HIV; ANI,
asymptomatic NCI.
doi:10.1371/journal.pone.0002516.t001
Table 2. Distribution of patients with HAD and without
neurocognitive impairment (NCI) stratified by plasma LPS
levels.
Group A–high plasma LPS Group B-low plasma LPS
No NCI HAD No NCI HAD
n=18 n=31 n=18 n=8
AIDS patients with CD4 counts ,300 cells/ml were classified based on plasma
LPS levels at one (n=41) or two (n=17) visits into 2 groups (cutoff 79 pg/ml,
the median LPS value in the AIDS cohort). The distribution of patients with HAD
or without NCI in these 2 groups was analyzed for statistical significance using
the Chi-square test (p=0.007) and odds ratio (3.8, with 95% confidence interval
1.403–10.7) with Prism4 software. The distribution of patients with MCMD and
without NCI in the two groups was similar (p=0.8).
doi:10.1371/journal.pone.0002516.t002
Table 3. Distribution of patients with HAD and without
neurocognitive impairment (NCI) stratified by plasma sCD14
levels.
Group A–high plasma sCD14 Group B-low plasma sCD14
No NCI HAD No NCI HAD
n=12 n=23 n=24 n=16
AIDS patients with CD4 counts ,300 cells/ml were classified based on plasma
sCD14 levels at one (n=41) or two (n=17) visits into 2 groups (cutoff 2.4 mg/ml,
the median sCD14 value in the AIDS cohort). The distribution of patients with
HAD or without NCI in these 2 groups was analyzed for statistical significance
using the Chi-square test (p=0.026) and odds ratio (2.8, with 95% confidence
interval 1.121–7.376). The distribution of MCMD patients in the two groups was
similar (p=0.2).
doi:10.1371/journal.pone.0002516.t003
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PLoS ONE | www.plosone.org 4 June 2008 | Volume 3 | Issue 6 | e2516Figure 2. Substance abuse and HCV co-infection are associated with high plasma LPS levels. (A) CD4 counts and plasma levels of VL, LPS,
and sCD14 were compared in AIDS patients with or without substance abuse as indicated. (B) CD4 counts and plasma levels of VL, LPS, and sCD14
were compared in AIDS patients with IVDU heroin (H), cocaine (C), and H+C. (C) CD4 counts and plasma levels of VL, LPS, and sCD14 were compared
in AIDS patients with and without HCV co-infection. Median values are indicated as horizontal lines and statistical significance between groups was
calculated using the Mann-Whitney test; significant differences (p,0.05) are indicated.
doi:10.1371/journal.pone.0002516.g002
LPS and AIDS Dementia
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Plasma EndoCAb levels were not significantly different among
subject groups classified according to different patterns of
substance abuse (Figure 4E–F). Thus, LBP levels are higher in
HAD subjects compared to those with no NCI, and in subjects
with IV heroin or ethanol abuse compared to those with no
substance abuse.
Increased CD16
+ monocyte frequency is associated with
AIDS but not with HAD
In the pre-HAART era, preferential expansion of the CD16
+
Mo subset was associated with HAD a study by Pulliam et al. [6].
We therefore examined whether the CD16
+ Mo subset is
preferentially expanded in HAD subjects in the present study
cohort, and whether high LPS levels were associated with
preferential expansion of this Mo subset. In AIDS patients
recruited at the Shattuck Hospital (n=49), the frequency of Mo
expressing CD16 was significantly increased compared to
uninfected controls (Figure 5A), whereas absolute Mo counts were
similar in AIDS (3806166 cells/ml, n=37) and control subjects
(4356220 cells/ml, n=14; p=0.442) based on analysis of white
blood cell (WBC) counts. High plasma VL (cutoff 10,000 HIV
RNA copies/ml) was associated with an increased frequency of
CD16
+ Mo (median 20.5% versus 29%; p=0.01), together with
decreased CD4 counts (median 109 versus 27; p=0.006). The
frequency of CD16
+ Mo was high in both HAD and no NCI
subjects compared to uninfected controls, with no significant
difference between the HAD and no NCI groups (Figure 5B).
Plasma VL and CD4 counts were significantly increased
(p=0.025) and decreased (p=0.0009), respectively, in HAD
compared to no NCI subjects. Stratification of subjects according
to high versus low frequency of CD16
+ Mo (cutoff 22.5%, median)
demonstrated that CCL2 levels were slightly higher in subjects
with a high frequency of CD16
+ Mo (median 263 versus 165 pg/
ml, p=0.09), while LPS, sCD14, and IL-6 levels were not
significantly different. Thus, the CD16
+ Mo subset is expanded in
patients with AIDS, but expansion of this Mo subset is not
significantly different between HAD subjects and those with no
NCI in this study cohort.
Immune restoration in patients on HAART increases the
likelihood of neurocognitive recovery [38]. In addition to
decreased plasma VL and increased CD4 counts, patients on
HAART $8 weeks had a lower frequency of CD16
+ Mo, lower
LPS, and lower sCD14 levels compared to those on HAART ,8
weeks or not on HAART (Figure 5C). Comparison of LPS levels in
12 AIDS patients between two consecutive visits revealed a
significant decrease in LPS attributable to HAART ($8 wks)
(100.8 versus 84.7 pg/ml LPS, median, p=0.04), together with a
reduction in plasma VL (69,250 vs. 3,424 HIV RNA copies/ml,
median, p=0.04).
Mo from AIDS patients with HAD were analyzed for
expression of the activation markers HLA-DR, CD69, and the
HIV co-receptor CCR5. HLA-DR was expressed on .95% of Mo
from both HAD and control subjects but the MFI was higher in
HAD compared to control subjects (165669 vs. 66653, n=5–7,
p=0.03). The level of CD14 expression identified two CD16
+ Mo
subsets: CD14
highCD16
+ and CD14
lowCD16
+ [9,25], with prefer-
ential expansion of the CD14
highCD16
+ Mo subset in HAD
subjects (Figure 6A–B). CD69 expression was upregulated on all
three Mo subsets, whereas CCR5 expression was increased on
CD14
highCD16
2 and CD14
lowCD16
+ Mo from HAD compared
to control subjects (Figure 6C–D). These results indicate
Figure 3. Increased plasma lipopolysaccharide binding protein (LBP) levels in AIDS patients with HAD. (A) LBP levels were quantified in
plasma from AIDS patients (n=119) and uninfected controls (n=14) by ELISA. (B) Spearman correlation (r and p-values) was calculated to determine
relationships between LBP levels and plasma LPS. (C) LBP levels were compared between AIDS patients classified into 5 groups based on the level of
NCI as in Figure 1C or (D–E) classified into groups based on patterns of substance abuse as in Figure 2A–B. Median values are indicated as horizontal
lines and statistical significance between groups was calculated using the Mann-Whitney test; significant differences (p,0.05) are indicated.
doi:10.1371/journal.pone.0002516.g003
LPS and AIDS Dementia
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highCD16
+ Mo and activation of all
three Mo subsets in HAD patients.
Monocytes harbor low levels of HIV compared to CD4
+ T-
cells
To quantify HIV DNA and RNA levels in Mo and CD4
+ T-
cells isolated from peripheral blood, we used real time PCR/RT-
PCR. Relatively high levels of HIV DNA and RNA were detected
in CD4
+ T-cells from 8 of 8 and 4 of 6 AIDS patients, respectively,
whereas levels were below the limit of detection in Mo from 6 of 8
and 5 of 6 patients, respectively (Figure 7A–B). HIV DNA and
RNA levels in Mo were significantly lower compared to that in
CD4
+ T-cells from matched donors (Figure 7A–B). Replication-
competent HIV was isolated from CD4
+ T-cells, but not from
CD16
+ or CD16
2 Mo, in 4 of 5 donors (Figure 7C). Thus,
circulating Mo are a minor reservoir for HIV compared to CD4
+
T-cells in AIDS patients.
Discussion
In this study, we investigated the association between markers of
microbial translocation, alterations in circulating monocytes, and
neurocognitive impairment (NCI) in a cohort of AIDS patients with
a high frequency of IVDU and HCV co-infections and relatively
high plasma VL. High LPS and LBP together with decreased
EndoCAb levels were associated with increased sCD14 levels and
HIV-associated dementia (HAD). LPS levels were higher in AIDS
patients with IV heroinor ethanol abuse, or withHCVco-infection,
and were lower in patients on HAART, compared to control
groups. These findings support the idea that increased circulating
LPS, a consequence of microbial translocation, contributes to Mo
activation in chronic HIV infection/AIDS, as proposed by
Brenchley et al [1,3], and provide evidence that circulating LPS
may be linked to development of HAD via increased trafficking of
activated Mo into brain [7,20,21,22]. Our results also suggest that
cofactors linked to IV heroin and/or ethanol abuse and HCV co-
infection may influence these processes.
Plasma LPS levels are dramatically increased in certain
pathological conditions that include sepsis, inflammatory bowel
disease (IBD), graft versus host disease (GVHD), and HIV
infection [1,3]. The gastrointestinal tract is a major reservoir for
both commensal and pathogenic bacteria, in addition to being a
major site for HIV replication [1]. The level of microbial
translocation was previously correlated with immune activation
and CD4
+ T cell depletion in HIV-infected patients [1,3,39].
Here, we demonstrate that high plasma LPS levels, together with
increased Mo activation markers (i.e., sCD14, CCL2, and IL-6),
are associated with HAD and/or minor cognitive and motor
disorder (MCMD). LPS levels predicted HAD independently of
VL and CD4 counts, whereas sCD14 levels predicted HAD
independently of VL but in relationship with CD4 counts and
plasma IL-6 and CCL2 levels. We also found an association
between high VL or low CD4 counts and HAD, consistent with
previous reports [20,21], indicating that both virologic and
immune control in the periphery are linked to key events involved
in HIV neuropathogenesis.
LBP, which is produced in the liver during the acute phase of
infections, binds to LPS and triggers CD14-dependent Mo
Figure 4. Decreased plasma IgM endotoxin core antibody (EndoCAb) levels in AIDS patients with HAD. (A) Levels of IgM EndoCAb were
quantified in plasma from AIDS patients (n=119) and uninfected controls (n=14) by ELISA. (B) Spearman correlation (r and p-values) was calculated
to determine relationships between IgM EndoCAb levels and plasma LPS. (C) IgM EndoCAb levels were compared between AIDS patients classified
into 5 groups based on the level of NCI as in Figure 1C or (D–E) classified into groups based on patterns of substance abuse as in Figure 2A–B.
Median values are indicated as horizontal lines and statistical significance between groups was calculated using the Mann-Whitney test; significant
differences (p,0.05) are indicated.
doi:10.1371/journal.pone.0002516.g004
LPS and AIDS Dementia
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significance in patients with sepsis [37]. Plasma LBP levels are
increased in HIV-infected patients and correlate positively with
the degree of microbial translocation [3]. Consistent with these
results, we found a direct correlation between LPS and LBP levels
in AIDS patients. In addition, we demonstrated that increased
LBP levels are associated with HAD. Plasma levels of immuno-
globulin-M (IgM) antibodies to the LPS core oligosaccharide
(EndoCAb), which are normally present in human plasma and
potently inhibit LPS activity [41], were significantly decreased in
AIDS patients, consistent with the study by Brenchley et al. [3],
probably a consequence of altered B cell function in HIV-infected
individuals [42,43]. EndoCAb levels were slightly lower in HAD
subjects compared to those with no NCI, consistent with a
previous study which found that HAD patients contain lower
levels of anti-HIV neutralizing antibodies in plasma compared to
non-HAD patients [44]. Together, these results support the idea
that translocation of bacterial products from the gut or other
mucosal sites in AIDS patients contributes to events involved in
the development of HAD.
AIDS subjects with IV heroin or ethanol abuse had higher LPS
and LBP levels compared to those with no substance abuse. Plasma
LPS levels were previously reported to be increased in ethanol
abusers and in HCV infection as a consequence of increased gut
permeability and/or decreased hepatic function [45,31,32,46].
Possible reasons for high plasma LPS in IV heroin users include
increased susceptibility to bacterial infections [29,30], high
frequency of HCV co-infection, and reduced immune responses
[30,47]. Studies on the relationship between substance abuse and
HIV disease progression reached different conclusions, probably
due to different study designs and methodological limitations
[29,30,48]. Our results together with previous reports that found a
higher incidence or more rapid progression of HAD in IVDU
[49,50,51] suggest that high levels of LPS may contribute to an
increased frequency of NCI in heroin IVDU compared to non-
IVDU AIDS patients. LPS levels were higher in patients with HCV
Figure 5. Increased CD16
+ monocyte frequency in AIDS patients with and without HAD. (A) The frequency of CD16
+ Mo within the total
Mo population was analyzed in AIDS (n=38) and uninfected subjects (n=25). Total and CD16
+ Mo were distinguished from granulocytes by HLA-DR
and lack of CD16b/CD66b expression, and from NK cells by higher forward and side scatter characteristics (FSC and SSC), CD14, CD4, and CD33, and
lack of CD56 expression [25]. (B) The frequency of CD16
+ Mo was compared in AIDS patients with HAD (n=29) and no NCI (n=9). (C) The frequency
of CD16
+ Mo, plasma VL, and plasma levels of LPS and sCD14 were compared in patients receiving HAART $8 weeks (wks) and untreated or on
HAART ,8 wks. Median values are indicated as horizontal lines and statistical significance between groups was calculated using the Mann-Whitney
test; significant differences (p,0.05) are indicated.
doi:10.1371/journal.pone.0002516.g005
LPS and AIDS Dementia
PLoS ONE | www.plosone.org 8 June 2008 | Volume 3 | Issue 6 | e2516coinfection than in HCV-negative subjects, consistent with previous
studies that found endotoxemia during HCV infection [32,46].
Thus, circulating LPS may contribute to the increased incidence of
NCI that has been observed in association with HIV/HCV co-
infection [33,34,35]. Surprisingly, sCD14 levels were not increased
in AIDS patients with substance abuse or HCV coinfection;
however, these subjects had higher CD4 counts and lower plasma
VL compared to control groups, indicating a less advanced stage of
HIV disease. Mo sensitivity to LPS stimulation is influenced by host
factors that include receptor expression levels (e.g., CD14 and
TLR4) and intracellular signaling pathways that control the balance
between pro- (e.g., IRAK-4) [52] and anti-inflammatory responses
(e.g., IRAK-M) [53]. Moreover, cytokines such as M-CSF, IFN-c,
and CCL2, which are increased in blood and other tissues during
HIV/AIDS disease progression, can enhance monocyte sensitivity
to LPS stimulation [32,54,55,56]. Host factors and differences in
disease stage may therefore explain, at least in part, why increased
LPS was associated with higher sCD14 in subjects with HAD but
not substance abuse or HCV coinfection compared to control
groups.
In contrast to a study in the pre-HAART era [6], we found a
similar high frequency of circulating CD16
+ Mo in HAD and non-
HAD patients. These different results may relate to HAART [57],
phenotypic analysis of PBMC versus whole blood [6], or the high
frequency of IVDU in our cohort. We found an association
between an increased frequency of CD16
+ Mo and elevated
plasma CCL2, which may be relevant for neuropathogenesis, since
high CCL2 levels have been associated with an increased risk of
developing HAD [58] and CD16
+ Mo produce CCL2 [28].
CD16
+ Mo may contribute to HAD via trafficking into brain and
differentiating into activated perivascular macrophages [25],
which may promote CNS injury via production of CCL2, IL-6,
and MMP-9 [28], and other mechanisms [7,20,21,22].
Previous studies linked Mo activation [6,7,59] and increased
plasma sCD14 [60] and CCL2 levels [58] to an increased risk of
developing HAD. We found that HLA-DR and CD69 were
upregulated on all Mo subsets in HAD subjects, indicating a
general state of Mo activation. CCR5 was also upregulated, which
may increase Mo susceptibility to HIV infection and trafficking
into tissues [14]. We found an association between HAD and
increased plasma sCD14 and CCL2, which are soluble markers of
Mo activation [58,60,61]. LPS levels correlated positively with
sCD14 but not CCL2 levels, suggesting that LPS triggers Mo
release of sCD14 [3], while CCL2 may be induced by stimuli other
than LPS [28]. LPS stimulates leukocyte recruitment into the CNS
[62], and may also increase blood-brain barrier (BBB) permeabil-
ity [63]. Thus, circulating LPS may contribute to HAD
pathogenesis by several mechanisms.
HIV DNA and RNA were low in circulating Mo compared to
CD4
+ T-cells, suggesting that Mo represent a minor site for HIV
replication compared to CD4
+ T-cells in AIDS patients. Some
studies reported that circulating Mo, particularly the CD16
+ Mo
subset [15,16], harbor HIV DNA in some AIDS patients [13,14],
while others found little or no detectable HIV DNA in circulating
Mo [12,64]. Possible reasons for these different results include
differences in Mo isolation techniques, frequency of contaminating
CD4
+ T-cells, and sensitivity of HIV detection assays. Our results
are consistent with previous studies indicating that Mo contribute
Figure 6. Upregulation of CD69 and CCR5 expression on CD16
+ and CD16
2 monocyte subsets. (A) PBMC from AIDS subjects were
stained with fluorochrome-conjugated Abs. CD14 and CD16 expression identified three Mo subsets: CD14
highCD16
2 (gate R2), CD14
highCD16
+ (gate
R3), and CD14
lowCD16
+ (gate R4). (B) The frequency of each Mo subset was compared in AIDS (n=11) and uninfected subjects (n=8). The expression
of CD69 (C) and CCR5 (D) was analyzed for each Mo subset from AIDS (n=9–11) and uninfected subjects (n=5–9). Median values are indicated as
horizontal lines, and statistical significance in 6B–D was calculated using the Mann-Whitney test.
doi:10.1371/journal.pone.0002516.g006
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and differentiating into tissue macrophages that are highly
susceptible to infection [17,18].
Our results argue in favor of a link between microbial
translocation and systemic immune activation [1,3], and suggest
that LPS-induced Mo activation is associated with HIV disease
progression. We provide evidence that high LPS and LBP levels,
together with increased levels of Mo activation, represent
interrelated risk factors for HAD. Accordingly, the balance
between pro- and anti-inflammatory TLR signaling pathways
triggered in response to bacterial products may influence the
development of HAD. New approaches to downmodulate LPS-
induced Mo activation may provide new strategies for anti-HIV
and HAD therapy.
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